Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Filings indexed 339 across all filing types
Latest filing 2025-10-29 Interim / Quarterly Rep…
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the third quarter 2025' and contains comprehensive financial statements, including key figures, income statements, cash flow, and management commentary on business performance. It is clearly a quarterly financial report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report (IR). Q3 2025
2025-10-29 English
Korrigering - Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien är på god väg mot öppning i början av 2026 - Attachment: Inif
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport tredje kvartalet 2025' (Interim Report for the third quarter of 2025) for Inify Laboratories. It contains detailed financial statements, key performance indicators (KPIs), management commentary on business development, and operational updates for the specified period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q3 2025
2025-10-29 Swedish
Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026 - Attachment: Inify_Laboratories_Financial_Report_Q3_2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the third quarter 2025' and contains comprehensive financial statements, including key figures, income statements, cash flow, and management commentary on business performance. It is clearly a quarterly financial report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report (IR). Q3 2025
2025-10-29 English
Correction - Inify Laboratories: Første gastrointestinale diagnoser levert og klinisk virksomhet i Storbritannia i rute mot lansering tidlig i 2026 - Attachment: Inify_Laboratories_Financial_Report_Q3
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the third quarter 2025' and contains comprehensive financial statements, including key figures, income statements, cash flow, and management commentary on business performance. It is clearly a quarterly financial report, not an announcement or a summary, and meets the criteria for an Interim/Quarterly Report (IR). Q3 2025
2025-10-29 English
Korrigering - Inify Laboratories: De första diagnoserna inom mag-tarmområdet har levererats och den kliniska verksamheten i Storbritannien är på god väg mot öppning i början av 2026
Earnings Release Classification · 100% confidence The document is a correction notice regarding a previously published Q3 2025 quarterly report. It explicitly states that a correction is being made to the personnel costs in the parent company's income statement. Since it is a regulatory announcement regarding a financial report correction rather than the report itself, and it does not fit into specific categories like M&A or dividends, it is classified as a general regulatory filing. Q3 2025
2025-10-29 Swedish
Correction - Inify Laboratories: First gastrointestinal diagnoses delivered and UK clinical operations on track for launch early 2026
Earnings Release Classification · 100% confidence The document is a correction notice regarding a previously published Q3 2025 financial report. It provides a brief update on operational progress (UK expansion, gastrointestinal diagnostics) and financial highlights, but it is primarily an announcement of a correction to a previously released filing. Given its length (under 5,000 characters) and its nature as a regulatory disclosure of a correction, it fits best as a general regulatory filing. Q3 2025
2025-10-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.